Arterial (AT) and venous (VT) thrombotic events are the most common complications in
patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality …

The number of patients with myelofibrosis (MF) undergoing an allogeneic hemopoietic stem
cell transplantation (HSCT) is increasing: in the analysis of the European Group for Blood …

Classic Philadelphia-negative myeloproliferative neoplasms (MPN) include polycythemia
vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), classified as primary …

Ruxolitinib is a recommended second-line treatment for the prevention of thrombosis in
patients with polycythemia vera who become resistant or intolerant to hydroxyurea; however …

Pre-fibrotic myelofibrosis (pre-PMF) and essential thrombocythemia (ET) are characterized
by similarly increased rate of thrombotic events, but no study specifically analyzed risk …

We collected 1500 patients with myeloproliferative neoplasms (MPN) and arterial or venous
thrombosis (935/565), pooling three independent cohorts previously reported. Long-term …

Patients with essential thrombocythemia (ET) are treated with once‐daily low‐dose aspirin
to prevent thrombosis, but their accelerated platelet turnover shortens the antiplatelet effect …

Anemia is a frequent manifestation of myelofibrosis (MF) and there is an unmet need for
effective treatments in anemic MF patients. The REALISE phase 2 study (NCT02966353) …

Polycythemia vera (PV) is a BCR-ABL1-negative myeloproliferative neoplasm (MPN)
characterized by excessive proliferation of erythroid, myeloid, and megakaryocytic …

Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative
neoplasms characterized by increased rate of cardiovascular events, a varying burden of …